期刊文献+

高三尖杉酯碱对K562细胞NF-κB和BCL-2蛋白表达的影响 被引量:5

Effect of Homoharringtonine on Expression of NF-κB and BCL-2 Proteins in K562 Cells
下载PDF
导出
摘要 本研究旨在探讨高三尖杉酯碱(HHT)对K562细胞增殖、凋亡及BCL-2和NF-κB蛋白表达的影响。不同浓度HHT作用K562细胞后用MTT法、流式细胞仪、Western blot等方法分别检测细胞增殖、凋亡、BCL-2及NF-κB蛋白表达水平。结果表明,HHT作用48 h,浓度依赖性抑制K562细胞增殖,IC50为43.89 ng/ml。HHT 10 ng/ml作用48 h,K562细胞凋亡率明显增高;细胞周期阻滞于G0/G1期;BCL-2和NF-κB蛋白表达水平明显低于对照组(P<0.05)。结论:HHT对K562细胞有显著的增殖抑制、细胞周期阻滞和凋亡诱导作用,抑制NF-κB和BCL-2表达可能是其抗CML的机制之一。 This study was aimed to investigate the effect of homoharringtonine (HHT) on K562 cell proliferation, apoptosis and expression of BCL-2 and NF-κB proteins. The cells proliferation was assayed with MTT method, the cell apoptosis, cell cycle and BCL-2 expression were analyzed with flow cytometry, NF-κB protein expression was detected with Western blot. The results showed that HHT concentration-denpendently inhibited proliferation of K562 cells, the IC50 at 48 h was 43.89 ng/ml. Treated with HHT 10 ng/ml for 48 h, K562 cell apoptosis significantly increased, cell cycle was blocked at G0/G1 , the expression level of BCL-2 and NF-κB proteins was lower than that in control group(P 〈 0.05 ) . It is concluded that HHT may inhibit the proliferation of K562 cells, and down-regulating expression levels of BCL-2 and NF-κB may be one of its anti-CML mechanisms.
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2013年第1期78-81,共4页 Journal of Experimental Hematology
基金 江苏省淮安市科技支撑计划(编号HAS2010025)
关键词 高三尖杉酯碱 K562细胞 BCL-2 NF-ΚB homoharringtonine K562 cell BCL-2 NF-κB
  • 相关文献

参考文献3

二级参考文献37

  • 1Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330-1340.
  • 2Druker B J, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
  • 3Kantarjian HM, Giles F, QuintUs Cardama A, Cortes J. Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res 2007; 13: 1089-1097.
  • 4Feldman E, Arlin Z, Ahmed T, Mittelman A, Puccio C, Chun H, et al. Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia. Leukemia 1992; 6: 1189-1191.
  • 5O'Brien S, Kantarjian H, Koller C, Feldman E, Beran M, Andreeff M, et al. Sequential homoharringtonine and interferon-α in the treatment of early chronic phase chronic myelogenous leukemia. Blood 1999; 93: 4149-4153.
  • 6O'Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson LE, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995; 86: 3322-3326.
  • 7Quintas Cardama A, Cortes J. Homoharringtonine for the treatment of chronic myelogenous leukemia. Expert Opin Pharmacother 2008; 9: 1029-1037.
  • 8Quintas Cardama A, Kantarjian H, Garcia Manero G. O'Brien S, Faderl S, Estrov Z, et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007; 109: 248-255.
  • 9Marin D, Kaeda JS, Andreasson C, Saunders SM, Bua M, Olavarria E, et al. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer 2005; 103: 1850-1855.
  • 10Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in "good risk" chronic granulocytic leukemia. Blood 1984; 63: 789-799.

共引文献20

同被引文献61

引证文献5

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部